YAP1 and obesity disorder: We also identify Retatrutide, an anti‐obesity agent, as a novel therapeutic intervention that reduces YAP O‐GlcNAcylation and promotes ubiquitylation, disrupting YAP stabilization in the obese tumor microenvironment.